Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies

Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.